The Safety and Efficacy of ZelanteDVT™ Catheter Rheolytic Thrombectomy in the Treatment of Patients with Iliac Vein Stent Thrombosis

Abstract

ObjectiveTo examine the safety and efficacy of ZelanteDVT™ catheter rheolytic thrombectomy in the treatment of patients with iliac vein stent thrombosis. MethodsA retrospective analysis method was conducted by means of collecting the data of 32 patients who had completed the treatment of iliac vein stent thrombosis with ZelanteDVT™ catheter rheolytic thrombectomy from March 2019 to March 2023. Data on clinical characteristics, technical success, clinical success, complications, and early follow-up were analysed. ResultsThe technical success rates were 100%, intraoperatively, in which 22 cases were improved to thrombus clearance Grade II (50-90%), 10 were Grade III (＞90%). There were 21 cases treated with subsequent catheter directed thrombolysis (CDT), and the average urokinase administration of (120.90±29.63)*10ˆ4 units. The clinical success rates were 100% and the swelling of the affected limbs were significantly improved, a significant difference in the pre/post-operative between-thigh circumference difference [(5.16±1.08) vs (1.75±0.84), P＜0.000]. The pre/post-operative VCSS was [ (12.94±1.70) vs (7.44±1.31), P＜0.000]. No serious complications occurred during the perioperative period. The post-operative and 12-month stent patency rate was 100.00% (32/32) and 71.88% (23/32), respectively. ConclusionThe ZelanteDVT™ catheter rheolytic thrombectomy seems to have a promising application prospect for the treatment of patients with iliac vein stent thrombosis.